This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| EQT Life Sciences | |
|---|---|
| Name | EQT Life Sciences |
| Type | Private equity fund |
| Industry | Life sciences investing |
| Founded | 2020 |
| Headquarters | Stockholm, Sweden |
| Area served | Global |
| Products | Growth equity, venture capital, buyouts |
EQT Life Sciences EQT Life Sciences is a prominent private equity strategy focused on biotechnology, pharmaceutical industry, medical device companies and healthcare-related services. It operates within the broader EQT AB group and targets companies across Europe, North America, and Asia. The strategy draws on relationships with academic institutions, multinational corporations, and government-funded research bodies to identify transformative technologies in therapeutics, diagnostics, and platform technologies.
EQT Life Sciences pursues growth-oriented investments in companies spanning biotech startups, clinical research organizations, medtech firms and healthcare services providers. It leverages expertise from teams with backgrounds at institutions like Karolinska Institutet, Harvard University, Johns Hopkins University, Massachusetts Institute of Technology, and Imperial College London. The team collaborates with corporate partners including Roche, Novartis, Pfizer, GlaxoSmithKline, and Johnson & Johnson to support scaling, regulatory strategy, and commercialization. Its investment activity is situated amid ecosystems featuring players such as Cambridge Biomedical Campus, BioNTech, Moderna, Genentech, and Regeneron.
EQT Life Sciences was launched as a dedicated strategy in 2020 under the umbrella of EQT AB, following precedents set by life sciences investment arms at firms like SV Health Investors, OrbiMed Advisors, Avista Capital Partners, and Perceptive Advisors. Early activity referenced deal flow channels from university spinouts at Uppsala University, University of Oxford, University of Cambridge, ETH Zurich, and University of California, Berkeley. The strategy built on earlier private equity movements exemplified by transactions involving Actelion, Alnylam Pharmaceuticals, Shire, and AstraZeneca acquisition trends. Leadership drew from alumni of KKR, Carlyle Group, TPG Capital, and Bain Capital Life Sciences.
EQT Life Sciences emphasizes value creation through clinical and commercial milestones in company development akin to approaches used by Blackstone Life Sciences and Novo Holdings. Target sectors include novel modalities like gene editing associated with CRISPR Therapeutics, cell therapy reminiscent of Gilead Sciences acquisitions, RNA therapeutics as seen with Moderna, and diagnostics in the mold of Abbott Laboratories. Portfolio companies span preclinical innovators, late-stage clinical assets, and commercial-stage medtech firms. Investment processes engage regulatory expertise informed by precedents at European Medicines Agency and U.S. Food and Drug Administration, and leverage partnerships with Bill & Melinda Gates Foundation, Wellcome Trust, and commercial partners such as Siemens Healthineers and Thermo Fisher Scientific.
EQT Life Sciences operates funds raising capital from institutional limited partners including pension funds, sovereign wealth funds, insurance companies like Allianz, and endowments linked to institutions such as Yale University and Stanford University. Fund vehicles follow limited partnership formats used across private equity, with return targets benchmarked against indices like the NASDAQ Biotechnology Index and S&P 500. Performance metrics reference internal rate of return comparable to peers including BridgeBio, Flagship Pioneering-backed exits, and historical returns from TPG Capital life sciences funds. Capital deployment includes primary investments, follow-on funding, and syndication with co-investors including Sequoia Capital, Insight Partners, Accel Partners, and Index Ventures.
The strategy is overseen by executives with prior roles at firms such as EQT AB, KKR, Bain Capital, and academic appointments at Karolinska Institutet and University College London. Investment committees include experts in translational medicine from Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Mayo Clinic. Advisory boards draw on leaders from European Investment Bank-backed initiatives, representatives of Novo Nordisk Foundation, and former regulators from European Medicines Agency and U.S. Food and Drug Administration. Operating partners often include former executives of Roche, Sanofi, Eli Lilly and Company, and Bristol Myers Squibb.
EQT Life Sciences has been associated with investments and exits reminiscent of high-profile transactions such as Gilead’s acquisition history, Roche’s strategic buys, and public listings similar to BioNTech and Moderna. Portfolio activity includes backing companies developing oncology therapeutics akin to Bristol Myers Squibb targets, rare disease programs parallel to Vertex Pharmaceuticals approaches, and medical device firms like those spun out from Boston Scientific and Medtronic. Exits have involved strategic sales to multinational pharmaceutical companies and initial public offerings on exchanges like Nasdaq and London Stock Exchange.
As with peers Blackstone, Carlyle Group, and KKR, life sciences funds face scrutiny over valuation practices, intellectual property licensing disputes, and portfolio company restructuring. Controversies in the sector have included debates involving drug pricing exemplified by disputes around Martin Shkreli-era price hikes, patent litigation similar to Amgen v. Sanofi, and concerns raised by public health advocates and policymakers in bodies such as the European Parliament and U.S. Congress. Regulatory scrutiny from institutions like the European Medicines Agency and U.S. Food and Drug Administration shapes oversight and public debate about private equity’s role in healthcare innovation.
Category:Private equity firms Category:Life sciences Category:Investment companies of Sweden